Synchroneuron Inc. Report issue

For profit Phase 2
Founded: Newton MA United States (2011)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2014
NCT02064010
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

acamprosate (campral) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Combat Disorders (Phase 2)

Disease (Phase 2)

Dyskinesias (Phase 2)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Syndrome (Phase 2)

Tardive Dyskinesia (Phase 2)

Tourette Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1